Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity

The endocannabinoid system has been suspected to contribute to the association of visceral fat accumulation with metabolic diseases. We determined whether circulating endocannabinoids are related to visceral adipose tissue mass in lean, subcutaneous obese, and visceral obese subjects (10 men and 10 women in each group). We further measured expression of the cannabinoid type 1 (CB1) receptor and fatty acid amide hydrolase (FAAH) genes in paired samples of subcutaneous and visceral adipose tissue in all 60 subjects. Circulating 2-arachidonoyl glycerol (2-AG) was significantly correlated with body fat (r = 0.45, P = 0.03), visceral fat mass (r = 0.44, P = 0.003), and fasting plasma insulin concentrations (r = 0.41, P = 0.001) but negatively correlated to glucose infusion rate during clamp (r = 0.39, P = 0.009). In visceral adipose tissue, CB1 mRNA expression was negatively correlated with visceral fat mass (r = 0.32, P = 0.01), fasting insulin (r = 0.48, P < 0.001), and circulating 2-AG (r = 0.5, P < 0.001), whereas FAAH gene expression was negatively correlated with visceral fat mass (r = 0.39, P = 0.01) and circulating 2-AG (r = 0.77, P < 0.001). Our findings suggest that abdominal fat accumulation is a critical correlate of the dysregulation of the peripheral endocannabinoid system in human obesity. Thus, the endocannabinoid system may represent a primary target for the treatment of abdominal obesity and associated metabolic changes.

[1]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[2]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  C. Cannon,et al.  Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. , 2006, Journal of the American College of Cardiology.

[4]  J. Klein,et al.  Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[6]  B. Scatton,et al.  The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics , 2022 .

[7]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[8]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[9]  J. Després,et al.  Is visceral obesity the cause of the metabolic syndrome? , 2006, Annals of medicine.

[10]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[11]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[12]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[13]  P. Soubrié,et al.  The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  A. Gerber,et al.  Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.

[15]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[16]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[17]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[18]  M. Stock,et al.  Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.

[19]  K. Mackie,et al.  Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension , 2004, Circulation.

[20]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[21]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[22]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[23]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[24]  A. Finazzi-Agro’,et al.  Leptin Activates the Anandamide Hydrolase Promoter in Human T Lymphocytes through STAT3* , 2003, The Journal of Biological Chemistry.

[25]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[26]  D. Cota,et al.  Endogenous cannabinoid system as a modulator of food intake , 2003, International Journal of Obesity.

[27]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[28]  Lei Wang,et al.  Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[30]  P. Widdowson,et al.  Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? , 2002, Brain Research.

[31]  B. Cravatt,et al.  Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. , 2002, The Journal of pharmacology and experimental therapeutics.

[32]  V. Marzo,et al.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.

[33]  N. Jamshidi,et al.  Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats , 2001, British journal of pharmacology.

[34]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[35]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[36]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[37]  J. Widimský,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1998, Diabetes Care.

[38]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[39]  M. Storr,et al.  Release of anandamide from blood cells , 2006, Clinical chemistry and laboratory medicine.

[40]  T. Bisogno,et al.  Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. , 2005, Molecular human reproduction.

[41]  C. Hillard,et al.  Modulators of endocannabinoid enzymic hydrolysis and membrane transport. , 2005, Handbook of experimental pharmacology.